<?xml version="1.0" encoding="UTF-8"?>
<p>The first cohort study about neurological manifestations of COVID-19 summarized the neurological symptoms among 78 out of the 214 (36.4%) patients hospitalized in three designated COVID-19 hospitals in China.
 <sup>
  <xref rid="bibr28-1756286420932036" ref-type="bibr">28</xref>
 </sup> Of those patients, 6 suffered from stroke, but milder neurological symptoms were more commonly reported in this cohort, such as dizziness, headache, muscle symptoms, hypogeusia and hyposmia. Interestingly, anosmia, hyposmia and dysgeusia affected such a significant number of patients worldwide that the American Academy of Otolaryngology â€“ Head and Neck Surgery proposed that these symptoms should be added to the list of screening tools for possible COVID-19 infection.
 <sup>
  <xref rid="bibr29-1756286420932036" ref-type="bibr">29</xref>,
  <xref rid="bibr30-1756286420932036" ref-type="bibr">30</xref>
 </sup> Mild neurological symptoms, such as headache (13.6%) and myalgias (14.9%), were also reported in another large case series, which summarized the clinical characteristics among 1099 COVID-19 patients.
 <sup>
  <xref rid="bibr31-1756286420932036" ref-type="bibr">31</xref>
 </sup> In addition, the most common (52%) symptoms of adult patients with COVID-19 infection were myalgia and fatigue in a recent Chinese study.
 <sup>
  <xref rid="bibr32-1756286420932036" ref-type="bibr">32</xref>
 </sup> It is unknown whether these symptoms represent a systemic inflammatory state, neurological disease or both.
</p>
